Cantor Fitzgerald, L. P. Entrada Therapeutics, Inc. Transaction History
Cantor Fitzgerald, L. P.
- $8.4 Billion
- Q3 2025
A detailed history of Cantor Fitzgerald, L. P. transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 67,334 shares of TRDA stock, worth $570,318. This represents 0.0% of its overall portfolio holdings.
Number of Shares
67,334
Previous 67,334
-0.0%
Holding current value
$570,318
Previous $390,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding TRDA
# of Institutions
117Shares Held
27.9MCall Options Held
13.7KPut Options Held
14K-
Baker Bros. Advisors LP New York, NY4.87MShares$41.2 Million0.23% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$37.1 Million56.82% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.26MShares$36.1 Million16.56% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$14.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.6MShares$13.6 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $266M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...